On the complexity of oncology drug development
This article explains why so many compounds that cure cancer in lab mice fail in clinical trials, where some 95% flame out . The genes we thought were responsible for making the surviving of cancer essentials turn out to be insignificant.
HRT and breast cancer… the unfinished story
StatNews report on The Lancet study that reviewed data on more than 100,000 women who’d developed breast cancer after menopause. The study shows that 6,3% of women who never used HRT developed breast cancer versus 8,3% in women who used the combination of hormonal therapy…
« ASCO, The Woodstock of oncologists »
Some stats from STATnews The compounded annual growth rate in spending on oncology drugs is forecast to rise between 11% and 14%, bringing the total market to $200 billion to $230 billion. If you include supportive care, which is forecast to fall by as much…
Protected: The top 5 VR applications in healthcare
There is no excerpt because this is a protected post.